New test could sharpen diagnosis of narcolepsy and related sleep disorders

NCT ID NCT05615584

Completed Diagnosis Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study compares a new mass spectrometry technique to the standard radioimmunoassay for measuring orexin-A levels in cerebrospinal fluid. Orexin-A is a key brain chemical that is low in people with type 1 narcolepsy. The study involves 117 people with excessive daytime sleepiness who are undergoing a lumbar puncture as part of their evaluation. If the new method proves accurate, it could provide a more reliable and widely available diagnostic tool for narcolepsy and related hypersomnia disorders.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If the new mass spectrometry test proves accurate, it could offer a more accessible and reliable way to diagnose narcolepsy and other hypersomnia disorders.
What could go wrong: This is a diagnostic validation study, not a treatment trial. The new test may not be as accurate as the current method, and results may not change clinical practice immediately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates